chronic obstructive pulmonary disease

The Inhibitory Effects of Cordyceps militaris ARA301 Extract on Lipopolysaccharide-Induced Lung Injury in vivo

mycolabadmin

Researchers tested a mushroom extract from Cordyceps militaris to see if it could protect mice from lung injury caused by bacterial toxins. The extract successfully reduced inflammation, prevented excessive mucus production, and decreased immune cell buildup in the lungs. These findings suggest that this mushroom extract could potentially be used as a natural supplement to help prevent respiratory diseases and support lung health.

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

mycolabadmin

This article addresses confusion between two Aspergillus lung infections that commonly occur after tuberculosis: ABPA and CPA. While they have overlapping symptoms and test results, they require different treatments—ABPA responds to short-term steroids while CPA needs prolonged antifungal drugs. Importantly, giving steroids for misdiagnosed CPA can be harmful, so doctors should be cautious about diagnosing ABPA in tuberculosis survivors and consider CPA instead.

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

mycolabadmin

After tuberculosis treatment, some patients develop fungal lung infections that can look very similar to an allergic fungal disease called ABPA. This editorial warns doctors that they need to be careful about diagnosing ABPA in tuberculosis patients because treating it with the wrong medications could make the fungal infection worse. The key difference is that true ABPA causes wheezing and asthma-like symptoms, while post-TB fungal infections cause cavities and scarring in the lungs.

A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile

mycolabadmin

Researchers in Chile studied serious mold infections in 176 hospitalized patients (adults and children) over two years. They found that aspergillosis (a lung infection caused by Aspergillus mold) was the most common, especially in patients whose immune systems were compromised by cancer, transplants, or medications. Interestingly, nearly 40% of cases also involved COVID-19 infection. Although almost all patients received antifungal medications, survival rates were concerning, with about one-third of patients still alive after six months.

Graphene nanomaterials: A new frontier in preventing respiratory fungal infections

mycolabadmin

Graphene nanomaterials, especially nano-graphene oxide, show promise as new treatments for serious lung fungal infections that particularly threaten people with weakened immune systems. These tiny materials work by generating damaging reactive oxygen species that kill fungal cells and prevent biofilm formation. Unlike traditional antifungal drugs, nano-graphene oxide can be delivered directly to infected lung tissue via inhalation, delivering medicine exactly where needed while reducing harmful side effects throughout the body.

Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models

mycolabadmin

This study found that Armillaria mellea mushroom mycelia can help protect lungs from damage caused by PM2.5 air pollution. When tested in both laboratory cells and mice, the mushroom extract reduced inflammatory responses and restored healthy lung function. The protective effects work by reducing harmful inflammatory molecules and blocking inflammatory signaling pathways. These findings suggest A. mellea could be developed into a natural supplement to help protect respiratory health in areas with poor air quality.

Diagnostic performance of Aspergillus-specific immunoglobulin G immunochromatographic and enzyme-linked immunosorbent assay testing in chronic pulmonary aspergillosis: comparative analysis across subtypes and influencing factors

mycolabadmin

Chronic pulmonary aspergillosis (CPA) is a serious fungal lung infection that primarily affects people with existing lung conditions. This study compared two methods to detect the disease: a fast, portable test (ICT) and a traditional laboratory test (ELISA). The faster ICT test was more accurate overall and can provide results quickly in areas without advanced laboratory facilities. However, patients already taking antifungal medications had lower test accuracy with both methods.

Graphene nanomaterials: A new frontier in preventing respiratory fungal infections

mycolabadmin

Scientists are exploring nano-graphene oxide, a microscopic material made from graphene, as a new treatment for serious lung fungal infections. These tiny particles can kill fungal cells through multiple mechanisms and deliver antifungal drugs directly to infection sites while reducing harmful side effects. Researchers found that graphene oxide can be combined with existing antifungal medications to make them work better and even help overcome drug-resistant fungal infections.

Clinical characterization of immunocompetent patients with Scedosporium detected in respiratory samples: A case series

mycolabadmin

This study examined eight elderly patients without compromised immune systems who had Scedosporium fungus detected in their lungs. All patients had a condition called bronchiectasis and most had previously suffered from a lung infection called MAC disease. The researchers found that in most cases, the fungus was simply living in the lungs without causing active infection, though distinguishing between these two situations proved difficult. Only one patient was diagnosed with an active Scedosporium infection and required antifungal treatment with a drug called voriconazole.

Disease: chronic obstructive pulmonary disease